People: use cases, players, stakeholders.
Eight regulatory triggers that demand validated bioanalysis · the five player categories that run the field · who decides, who pays, who is liable.
Use cases: what BMV is actually for.
Eight regulatory triggers that demand validated bioanalysisBMV is not a research activity. It is a regulatory activity triggered by specific submission pathways. The trigger determines the scope, the timeline, and the inspection regime that will eventually look at the data.
PK supporting BE.
Generic sponsor triggers. ANDA / ANDE pathways depend on BE data integrity. The original use case that funded the entire bioanalytical CRO industry.
First-in-human FIH.
Mandatory ISR (7% samples). Pharma sponsor triggers. Risk mitigation at the start of clinical development. PK / PD baselines for dose-escalation decisions.
Biomarker qualification.
Context-of-use defined pre-validation. Biomarker becomes registrational endpoint. Pharma sponsor (oncology, rare disease) triggers. Increasingly tier-governed.
Reference standard characterisation.
Internal standards and reference materials must be validated under §5 QC requirements. CRO / pharma QA triggers. Ongoing support of approved methods.
Assay transfer.
Sponsor lab → CRO, CRO → CRO. Operational trigger when capacity or geography shifts. Increasingly flagged in PMDA inspections.
DBS & microsampling.
Population PK, paediatric, decentralised trials. Increasing operational trigger 2024+. New extraction-recovery and haematocrit-effect validation experiments required.
Biosimilar PK.
Comparative PK against reference. Immunogenicity assay validation under ADA framework (M10 §7). Distinct from small-molecule. Biologic sponsor triggers.
Post-approval method transfer.
Manufacturing scale-up, formulation change. Type I / II variation support. Ongoing pharma sponsor trigger across the product lifecycle.
Big players: who runs the field.
CROs · pharma · regulators · tech · academiaThe bioanalytical ecosystem has five player categories. Sponsors set the strategy and pay; CROs execute most validations; regulators define the surface; tech vendors own the instruments; academia supplies the foundational science and the early-career talent.
Stakeholders: interests & leverage.
Who decides · who pays · who is affectedEach stakeholder in a bioanalytical programme has a distinct interest and a distinct lever. Reading the politics of a study correctly means knowing whose lever fires when the trial is challenged.